Findings

What do systematic reviews say?

12 questions · 12 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 25%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 4 · 33.3%Moderate 3 · 25%High 0 · 0%

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Bevacizumab + IFN probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.68 [0.6, 0.77]
2 studies · 1381 participants
Moderate

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Bevacizumab + IFN may leads to lower overall survival (absolute effect size estimates based on survival… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.88 [0.79, 0.99]
2 studies · 1381 participants
Low

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.31 [1.2, 1.42]
2 studies · 1356 participants
Moderate

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether everolimus + bevacizumab changes progression‐free survival (absolute effect size estimates based on… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.91 [0.69, 1.2]
1 study · 365 participants
Very low

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

It is very uncertain whether everolimus + bevacizumab changes overall survival (absolute effect size estimates based on survival… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.01 [0.75, 1.36]
1 study · 365 participants
Very low

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Everolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.06 [0.95, 1.18]
1 study · 361 participants
Low

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Temsirolimus + bevacizumab showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.1 [0.9, 1.34]
1 study · 791 participants
Low

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.08 [0.9, 1.3]
1 study · 791 participants
Moderate

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.05 [0.98, 1.13]
1 study · 784 participants
Low

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found